【24h】

High sensitivity ELISA determination of taxol in various human biological fluids.

机译:各种人类生物液中紫杉醇的高灵敏度ELISA测定。

获取原文
获取原文并翻译 | 示例
           

摘要

Taxol (paclitaxel)--the natural product isolated from Pacific yew (Taxus brevifolia)--is a novel agent with high activity in the treatment of patients with several malignant tumors including those resistant to other cytotoxic drugs. The therapeutic index of this promising anticancer drug could be further increased by the exploration of its pharmacokinetic pharmacodynamic relationship in cancer patients. Since taxol is highly protein bound, a very specific and highly sensitive analytical method is required in order to determine free, protein unbound and biologically active taxol species in human physiological fluids: plasma; plasma ultrafiltrate; and salivary fluids. In order to accomplish this, a new indirect competitive enzyme-linked immunosorbent assay (ELISA), for quantitating such a low bioactive taxol concentration level, has been developed in our laboratories. This method uses taxol competitive inhibition of mouse anti-taxol antibodies binding to the solid phase coated antigen 7-succinyltaxol-bovine serum albumin. This indicates recognition of the active taxol in the solution phase, where a diluted horseradish peroxidase labeled goat anti-mouse enzyme conjugate is used. While employing this technique, after systematic optimization of the experimental conditions, we are able to detect the anticipated taxol in plasma ultrafiltrate and salivary fluids at the concentration level of subpicogram per milliliter. The working range of the assay is approximately five orders in magnitude, i.e. from pg ml(-1) to 100 ng ml(-1). The clinical part of this study verified the working range of the ELISA method using samples of physiological fluids from a cancer patient treated with 3 h intravenous (i.v.) infusion of this drug. Our results of taxol determination in plasma, plasma ultrafiltrate and saliva demonstrate the applicability of the newly developed ELISA method for further pharmacokinetic studies of free, biologically active taxol species in cancer patients.
机译:紫杉醇(紫杉醇)是从紫杉(Taxus brevifolia)中分离得到的天然产物,是一种新型的高活性药物,可治疗多种恶性肿瘤患者,包括对其他细胞毒性药物有抗药性的患者。通过探索其在癌症患者中的药代动力学药效关系,可以进一步提高这种有前途的抗癌药物的治疗指数。由于紫杉醇与蛋白质高度结合,因此需要一种非常专一且高度灵敏的分析方法来测定人体生理液中血浆中游离的,未结合蛋白质的生物活性紫杉醇种类。血浆超滤液;和唾液。为了实现这一目标,我们实验室中开发了一种新的间接竞争性酶联免疫吸附测定法(ELISA),用于定量测定如此低的生物活性紫杉醇浓度水平。该方法利用紫杉醇竞争性抑制小鼠抗紫杉醇抗体与固相包被的抗原7-琥珀酰紫杉醇-牛血清白蛋白结合。这表明在溶液相中对活性紫杉醇的识别,其中使用了稀释的辣根过氧化物酶标记的山羊抗小鼠酶结合物。在采用这项技术的同时,在对实验条件进行系统优化之后,我们能够检测到血浆超滤液和唾液中预期的紫杉醇浓度在每毫升亚皮下的浓度。测定的工作范围大约为五个数量级,即从pg ml(-1)到100 ng ml(-1)。这项研究的临床部分使用了经过3 h静脉(i.v.)输注这种药物治疗的癌症患者的生理液样本,验证了ELISA方法的工作范围。我们在血浆,血浆超滤液和唾液中紫杉醇测定的结果表明,新开发的ELISA方法可用于癌症患者中游离,具有生物活性的紫杉醇种类的进一步药代动力学研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号